Dabrafenib: First global approval

Drugs

Volumn 73, Issue 12, 2013, Pages 1367-1376

  Ballantyne, Anita D ^a   Garnock Jones, Karly P ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; DACARBAZINE; FLUOROURACIL; PANITUMUMAB; TAFINLAR; TRAMETINIB; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CHILL; COLORECTAL CANCER; CONSTIPATION; CONVULSION; COUGHING; DECREASED APPETITE; DEHYDRATION; DRUG APPROVAL; DRUG CLEARANCE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAPILLOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CARCINOMA; SKIN DEFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; HUMANS; IMIDAZOLES; MELANOMA; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883237132     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0095-2     Document Type: Article

References (27)

1. Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother. 2013;47(4):519-26.
2. Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013;14(2):280-92.
3. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60-9.
4. Laquerre S, Arnone M, Moss K, et al. A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf V600E mutation. [abstract no. B88]. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Nov 15 2009.
5. Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front. 2013;3:54.
6. ® (dabrafenib capsules): US prescribing information. 2013. http://us.gsk.com/products/assets/us-tafinlar. pdf. Accessed Jun 13 2013.
7. GlaxoSmithKline. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar(Rm) (dabrafenib) capsules and the first MEK-inhibitor Mekinist(Tm) (trametinib) tablets, approved by FDA as single-agent therapies [media release]. May 29 2013. http://www.gsk.com.
8. ® (lapatinib) [media release]. Jun 28 2013. http://www.gsk.com.
9. GlaxoSmithKline. Regulatory Update - GSK announces submissions in the EU and US for dabrafenib and trametinib [media release]. Aug 3 2012. http://www.gsk.com.
10. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
11. GlaxoSmithKline. GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma [media release]. Feb 7 2013. http://www.gsk.com.
12. GlaxoSmithKline. Regulatory update - GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma [media release]. Jul 09 2013. http://www.gsk.com.
13. Gentilcore G, Madonna G, Mozzillo N, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer. 2013;13:17.
14. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-901.
15. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-31.
16. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3 K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-20.
17. Nebot N, Ma B, Haney P, et al. Exposure-response modeling of the effect of dabrafenib, a braf inhibitor, on objective response rate (ORR) in patients with braf V600 mutation positive melanoma [abstract no. PII-37]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S65-6.
18. Nebot N, Chiu JS, Ma B, et al. Exposure-response analysis of the effect of dabrafenib, a braf inhibitor, on tumor size in patients with V600 braf mutation positive melanoma [abstract no. OII-B-1]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S51.
19. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703.
20. Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer. 2013;49(5):1073-9.
21. Long GV, Ascierto PA, Grob JJ, et al. Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436) [abstract no. 8518]. J Clin Oncol. 2012;30(15 Suppl.).
22. Nathanson KL, Martin A, Letrero R, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436) [abstract no. 8501]. J Clin Oncol. 2011;29(15 Suppl.).
23. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-95.
24. Azer M, Menzies A, Haydu L, et al. Patterns of progression in patients with V600 brafmutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). Asia Pac J Clin Oncol. 2012;8(Suppl. 2):48.
25. Weber JS, Flaherty KT, Infante JR, et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma [abstract no. 8510]. J Clin Oncol. 2012;30(15 Suppl.).
26. Corcoran RB, Falchook GS, Infante JR, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) [abstract no. 3528]. J Clin Oncol. 2012;30(15 Suppl.).
27. Response Genetics Inc. Response Genetics Signs Agreement with GlaxoSmithKline to provide proprietary BRAF mutational analysis technology [media release]. May 11 2013. http://www.responsegenetics.com.